Patients sue GLP-1 drugmakers, citing severe side effects | Morning in America
At least 3,000 patients have filed lawsuits against the companies behind GLP-1 weight loss drugs, alleging severe health risks, including blindness. NewsNation’s Brooke Shafer has the story on “Morning in America.” Start your day with “Morning in America,” NewsNation’s live three-hour national morning newscast hosted by Markie Martin. Weekdays starting at 6a/5C. #MorningInAmerica NewsNation is […]
Patients sue GLP-1 drugmakers, alleging severe side effects
Some patients have pointed to severe undisclosed side effects, including blindness, loss of brain function and organ damage.
GLP-1 drugs might do what food policy can’t — change the way we eat
The desire for smaller portions and fewer junk foods is affecting what the food industry is selling us.
Here’s What Happens When You Stop Taking Ozempic and Wegovy – WSJ – The Wall Street Journal
Here’s What Happens When You Stop Taking Ozempic and Wegovy – WSJ The Wall Street Journal Hard truth about what happens when you stop weight loss injections Times of India Exclusive | GLP-1 drugs brought our eating disorders back — and quitting the shots doesn’t always help New York Post New Study of 77,000 Patients Reveals the Hard […]
Starting GLP-1s Leads to Healthier Choices at Grocery Store
The initiation of GLP-1 receptor agonists is associated with modest shifts away from ultraprocessed foods and toward items with fewer calories and smaller amounts of carbs, sugar, and saturated fat. Medscape Medical News
A small molecule PTER-selective inhibitor reduces food intake and body weight
PTER (phosphotriesterase-related) is an amidohydrolase that mediates catabolism of the anorexigenic taurine metabolite N-acetyltaurine. However, the structural basis of PTER ligand binding and catalysis remains unknown, limiting our ability to harness this pathway therapeutically. Here, we solve crystal structures of a eukaryotic PTER in apo and product-bound forms. These structures uncover an unexpected pocket homology […]
Navigating the complex relationship between statins, GLP-1, and glycemic control
A study linking statins, the microbiome, and blood sugar control doesn’t change clinical practice The post Navigating the complex relationship between statins, GLP-1, and glycemic control appeared first on Peter Attia.
Study raises red flags over long-term effectiveness of popular weight loss drugs like Ozempic
Ozempic, Mounjaro, and Zepbound can drive impressive weight loss, but stopping them is often followed by rapid weight regain. Researchers found that people regain weight faster after quitting these drugs than after diet and exercise alone. Improvements in heart health and diabetes risk also tend to reverse within a few years. The results suggest long-term success may require more than medication alone.
Incretin Based Therapy in Heart Failure with Preserved Ejection Fraction
Join the American Heart Association for an insightful session with Dr. Clyde Yancy and Dr. Dhruv Kazi. Recent clinical trials demonstrate the efficacy of incretin-based therapies (including GLP1-RA) in the care of HFpEF patients and their pivotal role in improving patient quality of life. Dr. Clyde Yancy discusses the latest evidence from these landmark trials […]
Arthur Brooks: Do GLP-1s Make Us Happy?
In my column last Monday, I wrote about how to make better New Year’s resolutions—ones that are less likely to flop, but that are also challenging enough to provide satisfaction. Why? Because accomplishing something with a degree of struggle is the way to realize joy. I gave the example of using GLP-1 drugs for weight […]